García-Aranda Marilina, Redondo Maximino
Research Unit, Hospital Costa del Sol. Autovía A7, km 187. 29603 Marbella, Málaga, Spain.
Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), 28029 Madrid, Spain.
Cancers (Basel). 2019 Mar 27;11(4):433. doi: 10.3390/cancers11040433.
Colorectal cancer is the third most common malignancy in men and the second most common cancer in women. Despite the success of screening programs and the development of adjuvant therapies, the global burden of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. In recent years, a great effort has been made to demonstrate the utility of protein kinase inhibitors for cancer treatment. Considering this heterogeneous disease is defined by mutations that activate different Receptor Tyrosine Kinases (RTKs) and affect downstream components of RTK-activated transduction pathways, in this review we analyze the potential utility of different kinase inhibitors for colorectal cancer treatment.
结直肠癌是男性中第三常见的恶性肿瘤，女性中第二常见的癌症。尽管筛查计划取得了成功，辅助治疗也有所发展，但预计到2030年，全球结直肠癌负担将增加60%，新增病例超过220万例，死亡110万例。近年来，人们付出了巨大努力来证明蛋白激酶抑制剂在癌症治疗中的效用。鉴于这种异质性疾病由激活不同受体酪氨酸激酶（RTK）的突变所定义，并影响RTK激活的转导途径的下游成分，在本综述中，我们分析了不同激酶抑制剂在结直肠癌治疗中的潜在效用。
